Two Directors Step Down from Elan Board in Accordance with Previously Announced Intention

Two Directors Step Down from Elan Board in Accordance with Previously Announced Intention
Company Confirms It Expects To Name New Chairman By Year End
DUBLIN, Nov 01, 2010 (BUSINESS WIRE) --

Elan Corporation, plc ("Elan") (NYSE: ELN) said today that two of its directors, Jack Schuler and Vaughn Bryson, resigned from the Board effective October 29, 2010, in accordance with their previously announced intention and their related agreements with Elan.


Separately, Elan confirmed that, as previously announced, it expects to name a new Chairman of the Board by year end.

About Elan

Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit www.elan.com.

Source: Elan Corporation, plc

 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.